Moderna's shares soared after positive developments in its cancer vaccine pipeline.
Moderna Inc. (NASDAQ:MRNA) saw a significant jump in its stock price, climbing 12.27% in yesterday's session. This rise was mainly fueled by encouraging results from its personalized cancer vaccine trials and positive regulatory news.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$77.78B
52W high
$195.71
52W low
$22.28
1W change
+23.25%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Sep 17, 2026
Wall Street analysts forecast MRNA stock price to fall 38.6% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$119.56
-38.6% Upside
Current Price
C$194.82
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
315.9%
Annualized
90-Day Vol
217.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$232.91
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$206.77 | C$69.53 – C$614.87 |
| 60 trading days | C$219.45 | C$46.99 – C$1024.90 |
| 90 trading days | C$232.91 | C$35.27 – C$1538.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are feeling more confident in Moderna as the company makes progress in its oncology pipeline, especially with its personalized cancer vaccine, intismeran autogene.
12.27%
Moderna's stock gained 12.27% yesterday, reflecting strong investor sentiment following positive trial results.
Bull case
The successful Phase 3 trial results for intismeran autogene, in partnership with Merck's Keytruda, have put Moderna in a strong position within the oncology market. This could lead to significant revenue growth in the future.
Bear case
Even with the recent surge, investors should stay cautious about the volatility of biotech stocks and the uncertainties in the broader market, particularly with rising interest rates.
Positive Trial Results
Advertisement
Moderna's stock surged after announcing successful Phase 3 trial results for its personalized cancer vaccine, intismeran autogene. The trial, conducted with Merck's Keytruda, showed significant improvements in patient outcomes, boosting optimism among investors.
Regulatory Developments
Alongside the trial results, Moderna received good news with the approval of its updated COVID-19 vaccines. This not only strengthens the company's product lineup but also signals growing trust from regulatory bodies in Moderna's capabilities.
Market Sentiment
The positive momentum in Moderna's stock reflects a broader recovery in investor sentiment towards biotech stocks. With ongoing advancements in its oncology pipeline, investors are increasingly optimistic about the company's future growth potential.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
